Lexaria Bioscience CORP 10-Q quarterly reports

Lexaria Bioscience reports reduced operating losses and increased cash reserves, but faces ongoing concerns about continuing as a going concern.

Lexaria Bioscience Corp. reported a significant decrease in revenue for the six months ended February 28, 2026, compared to the prior year, while strengthening its cash position through equity financings.

Lexaria Bioscience Corp. reported a reduced net loss in Q1 2026, driven by lower R&D expenses and recent capital raises, while advancing its DehydraTECH drug delivery technology for GLP-1 drugs and CBD for hypertension.

Lexaria Bioscience Corp. reported a significant increase in net losses for the nine months ended May 31, 2025, driven by substantial investments in research and development, while also raising substantial doubt about its ability to continue as a going concern.

Lexaria Bioscience Corp. announces its Q2 2025 financial results and provides updates on its DehydraTECH drug delivery technology, particularly its application with GLP-1 drugs for diabetes and weight loss.

Lexaria Bioscience Corp.'s latest 10-Q filing reveals increased research and development expenditures alongside promising results from animal and human studies of their DehydraTECH technology.

Lexaria Bioscience Corp. reports its Q3 2024 financial results, highlighting increased revenue and progress in research and development, while also noting ongoing losses and the need for additional funding.

Lexaria Bioscience Corp. released its financial results for the quarter ended February 29, 2024, highlighting increased revenue and progress in its research and development programs.

Lexaria Bioscience Corp. reported its financial results for the quarter ended November 30, 2023, showcasing increased revenue and advancements in its DehydraTECH technology.